reSee.it - Related Video Feed

The mRNA COVID vaccines were provisionally registered in 2018, allowing them on the market without full testing. The symbol on the box indicated reporting side effects was necessary, but many did not. The exact number of deaths and injuries is unknown. Rare side effects are being monitored after 14.7 billion doses administered. The lack of controlled data collection is criticized.

The Pfizer vaccine has undergone standard clinical trials and received provisional authorization in New Zealand. It is not considered to be in a trial period anymore. With hundreds of millions of doses administered worldwide, there have been no alarming or unexpected findings. The evidence gathered from these vaccinations aligns with what was observed during the clinical trials and in other countries.

Health Canada has authorized the new Moderna Spikevrax COVID-19 vaccine targeting the Omicron XBB1.5 subvariant for individuals aged 6 months and older. This decision follows a thorough independent review confirming the vaccine's safety, efficacy, and quality. The evidence indicates that the benefits of the vaccine outweigh potential risks. For individuals aged 5 and older, one dose is recommended, regardless of their previous COVID-19 vaccination history. Children aged 6 months to 4 years should receive two doses if they have not been previously vaccinated. If they have received one or more doses, they should get a single dose.

The Alberta government's COVID-19 response review calls for an immediate halt to modified RNA vaccines, particularly for children. The report, commissioned by Premier Danielle Smith, highlights significant data gaps regarding vaccine safety and effectiveness, citing alarming statistics from Pfizer's post-authorization trial, including over 1,200 deaths and 42,000 injuries. It criticizes the abandonment of Alberta's pandemic plan and urges a return to localized approaches. Recommendations include halting vaccine use without full risk disclosure, further research, and establishing support for vaccine-injured individuals. The review raises concerns about the lack of long-term safety data and the high risk of adverse events, particularly in young, healthy populations. It emphasizes the need for transparency and informed choice in future vaccination initiatives.

In this video, a diagnostic pathologist discusses the evidence presented by Pfizer to the FDA regarding COVID-19 vaccine trials in children aged 6 months to 4 years. The trial initially recruited 4,526 children, but 2,000 dropped out, raising concerns. The trial defined severe COVID as a slightly raised heart rate or increased breaths per minute. Six children in the vaccine group had severe COVID compared to one in the placebo group, suggesting a higher likelihood of the vaccine causing severe COVID. Additionally, 34 vaccinated children contracted COVID during the three-week period between doses, compared to 13 in the placebo group, indicating a 30% increased chance of catching COVID if vaccinated. The trial ignored significant data, ultimately comparing only three vaccinated children with COVID to seven in the placebo group to claim vaccine effectiveness.

In this video, a diagnostic pathologist discusses the evidence presented by Pfizer to the FDA regarding COVID-19 vaccine trials in children aged 6 months to 4 years. The trial initially recruited 4,526 children, but 2,000 dropped out without explanation. The trial defined severe COVID as a slightly raised heart rate or increased breaths per minute. Six children in the vaccine group had severe COVID compared to one in the placebo group, suggesting a higher likelihood of the vaccine causing severe COVID. Additionally, 34 vaccinated children contracted COVID during the three-week period between doses, compared to 13 in the placebo group, indicating a 30% increased chance of catching COVID if vaccinated. The trial ignored significant data and only compared small numbers, concluding that the vaccine was effective based on three cases in the vaccine group and seven in the placebo group.

Dr. Menares and an interlocutor debate the science behind pediatric COVID vaccination and routine immunizations, focusing on transmission, hospitalization, and risk. - The interlocutor asks whether the COVID vaccine prevents transmission. Speaker 1 answer: the vaccine can reduce viral load in individuals who are infected, and with reduced viral load, there is reduced transmission. The interlocutor reframes, insisting that the vaccine does not prevent transmission and notes decreasing effectiveness over time, citing Omicron data showing around 16% reduction when there is a reduction. - On hospitalization for children 18 and under: Speaker 0 asserts the vaccine does not reduce hospitalization for 18-year-olds; statistics are inconclusive due to small numbers of hospitalizations in that age group (approximately 76 million people aged 18 in the country, with 183 deaths and a few thousand hospitalizations in 2020–2021; numbers have since dropped). The argument emphasizes a need to discuss the issue. - On death for children 18 and under: Speaker 0 says the vaccine does not reduce the death rate; claims there is no statistical evidence that it reduces deaths. Speaker 1 responds with a more cautious stance: “It can,” but Speaker 0 counters, calling that an insufficient answer. - The discussion references the vaccine approval process and ongoing debates in vaccine committees. The interlocutor states that when the vaccine was approved for six months and older, the discussion acknowledged no proof of reduction in hospitalization or death. The argument asserts that the justification for vaccination is based on antibody generation rather than clear hospitalization/death data. The interlocutor contends that immunology measurements (antibody production) do not necessarily justify vaccination frequency. - The core debate centers on what the science supports for vaccinating six-month-olds and the benefits versus risks. The interlocutor argues there is no hospitalization or death benefit for vaccination in this age group, and notes a known risk of myocarditis in younger populations, estimated somewhere between six and ten per ten thousand, which the interlocutor claims is greater than the risk of hospitalization or death being measurable. - The exchange then shifts to changing the childhood vaccine schedule, particularly the hepatitis B vaccine given to newborns when the mother is not hepatitis B positive. The interlocutor asks for the medical or scientific reason to give a hepatitis B vaccine to a newborn with an uninfected mother, arguing that the discussion should focus on whether to change the schedule rather than declaring all vaccines as good or bad. - Speaker 1 says they agreed with considering the science and would not pre-commit to approving all ACIP recommendations without the science. Speaker 0 disagrees, asserting their position that the debate should center on the medical rationale for these specific vaccines and schedules, not on a blanket endorsement of vaccines. - Throughout, the dialogue emphasizes examining the medical reasons and evidence for specific vaccines and schedules, rather than broad generalizations about vaccines.

Pfizer presented evidence to the FDA on their trial for 6-month to 4-year-old children. Out of the 4,526 children recruited, 3,000 did not complete the trial, raising questions about the drop-off. The trial defined severe COVID as a slightly elevated heart rate or increased breaths per minute. In the vaccine group, 6 children aged 2 to 4 had severe COVID compared to only 1 in the placebo group. One child in the trial was hospitalized with fever and a seizure after being vaccinated. The trial manipulated the data by ignoring instances of COVID during specific time periods, ultimately disregarding 97% of the cases. Despite this, they concluded that the vaccine was effective based on a small number of cases.

Health Canada has authorized the Moderna Spikevax COVID-19 vaccine for individuals aged 6 months and older. The authorization followed a thorough scientific review of its safety, efficacy, and quality. The benefits of the vaccine were found to outweigh the potential risks. People aged 5 and above should receive one dose, regardless of their COVID-19 vaccination history. Children aged 6 months to 4 years should receive two doses if they haven't been previously vaccinated, and if they have, they should follow the recommended dosage.

The FDA has approved a new mRNA Moderna vaccine, despite known serious adverse events. The speaker expresses disappointment, suggesting the FDA is slow to change course. The approval letter concerns the speaker. The vaccine, MN spike, is an mRNA vaccine that produces spike protein, with lipid nanoparticles that will go everywhere. The manufacturer's data indicates serious adverse events were reported by 2.7% of participants receiving the new vaccine, compared to 2.6% for the older vaccine it replaces. The speaker finds it bemusing that a treatment with a 2.7% risk of serious adverse events would be authorized, unless there was a significant risk-benefit. The new vaccine (mRNA 1283) was compared to the old Moderna vaccine (mRNA 1273), not a placebo.

The TGA approved the Moderna COVID pediatric vaccine for children 6 months to 5 years based on the Kid COVE clinical trial. However, the vaccine is recommended only for high-risk children with serious comorbidities. The approval was made through the provisional pathway, which allows for approval based on interim clinical data. The TGA did not require patient-level data but relied on the clinical data provided by the sponsor. The Dane database holds reports of adverse events from both medical practitioners and the public, but the exact numbers are unknown. There is no evidence of a vaccine-cancer association, and the TGA's safety monitoring system is comprehensive. The TGA did not review the Pfizer vaccine from a cancer perspective. The accumulation of lipid nanoparticles in the body does not have adverse health effects. The TGA has not taken a position on vaccine mandates, and various agencies made their own decisions. The TGA rejects any suggestion of misfeasance and did not stop former Prime Minister Scott Morrison from making false statements about vaccine mandates.

Speaker 0 discusses the FDA approval of a new Moderna COVID vaccine, called MN Spike, for active immunization to prevent coronavirus disease. The speaker notes, “the messenger RNA coronavirus vaccine doesn't prevent infection and doesn't prevent transmission,” and says, “Yet here we are.” In the warnings and precautions section, the speaker states, “This product can cause myocarditis and pericarditis usually within the first week following vaccination.” They remark on ingredients, asserting, “Ingredients include polyethylene glycol, antifreeze,” and add, “Sure. Put that right into your body.” They claim the vaccine “codes for the spike glycoprotein,” and emphasize, “Remember, folks, this is the first time in human history that we have injected a product into the body that have forced our ribosomes, protein manufacturing machinery, to produce a nonhuman protein.” The speaker highlights section 13.1, asserting, “This product has not been evaluated for the potential for it to cause cancer.” They then say, “Well, actually, it has. These products now have been around for several years. Multi boosted people are showing an increased risk of cancer, often termed turbo cancer.” They argue that the warning should be changed to reflect that the product may cause cancer. Regarding studies, they claim, “not a single, not one randomized controlled trial against a placebo,” and ask, “What do they compare it to? The earlier version of their vaccine.” They conclude, “This is perfect. In my opinion, all COVID vaccines should pulled from the market immediately and a thorough investigation be launched.” They add, “Informed consent Friday. I hope this is helpful. Your comments are always appreciated. Take care.”

FDA, I don't know why, just approved a new Moderna COVID vaccine. Here is the package insert. It's called MN Spike. It's a vaccine indicated for active immunization to prevent coronavirus disease. This product can cause myocarditis and pericarditis, usually within the first week following vaccination. Ingredients include polyethylene glycol, antifreeze. And it codes for the spike glycoprotein. This is the first time in human history that we have injected a product into the body that have forced our ribosomes, protein manufacturing machinery, to produce a nonhuman protein. This product has not been evaluated for the potential for it to cause cancer. not a single, not one randomized controlled trial against a placebo. What do they compare it to? The earlier version of their vaccine. In my opinion, all COVID vaccines should be pulled from the market immediately and a thorough investigation be launched.

The Florida Department of Health, under Surgeon General Dr. Joseph Ladipo, published guidance on updated COVID-19 boosters. On August 22, 2024, the FDA approved updated mRNA vaccines from Pfizer/BioNTech and Moderna for ages 12+ and granted emergency use authorization for ages 6 months to 11 years. The guidance states the booster approval occurred without human clinical trial data and does not protect against the dominant strain, which accounts for 37% of US infections. There is limited data showing substantial protection against the virus or variants. The federal government hasn't required manufacturers to prove boosters prevent hospitalization or death, and has failed to provide sufficient safety and efficacy data or acknowledge safety concerns, including prolonged mRNA/spike protein circulation, increased risk of lower respiratory infections, and increased risk of autoimmune disease. The Florida Department of Health encourages healthcare providers to discuss this guidance with patients. Based on global immunity and available data, Dr. Ladipo advises against mRNA COVID vaccines. Providers concerned about high-risk patients should prioritize non-mRNA vaccines and treatments.

We couldn't find any prelicensing safety trials for the 72 vaccines doses that are recommended for American children. Unlike other medications, vaccines were exempt from conducting safety trials that compare health outcomes between a placebo group and a vaccine group. This lack of safety trials is concerning considering the widespread use of these vaccines.

Children aged 5 to 11 can now get the COVID vaccine to protect older and vulnerable individuals. The vaccine has low side effects, with only a few cases of heart inflammation out of millions vaccinated in the US. Getting COVID poses a higher risk of heart inflammation than the vaccine. Vaccinating kids can reduce school disruptions and help safeguard older people.

Pfizer presented evidence to the FDA on their trial for 6-month to 4-year-old children. Out of 4,526 children, 3,000 dropped out of the trial, which is concerning. The trial defined severe COVID as a slightly raised heart rate or increased breaths per minute. In the vaccine group, 6 children aged 2 to 4 had severe COVID compared to 1 in the placebo group. One child in the trial was hospitalized after vaccination. The trial twisted the data by ignoring cases of COVID during the 3-week gap between doses and the 8-week gap after the second dose. Ultimately, they only compared a small number of cases, claiming the vaccine was effective.

We couldn't find a prelicensing safety trial for any of the 72 vaccines doses recommended for American children. Unlike other medications, vaccines were exempt from conducting safety trials that compare health outcomes between a placebo group and a vaccine group.

According to VAERS, there have been 38,000 deaths from COVID shots, but instead of being pulled, the FDA has doubled down and put the shots on the childhood vaccine schedule. Babies are expected to get three COVID shots by nine months old. The shots are still under EUA status for the under 12 age group and are not fully FDA approved, yet they are on the vaccine schedule. The CDC states that nine million American children have received the latest version of these COVID shots. There is concern about myocarditis. It is believed that the shots should have been shut down a long time ago.

Health Canada has authorized the new Moderna Spike Brax COVID-19 vaccine for individuals aged 6 months and older. The vaccine underwent a thorough scientific review for safety, efficacy, and quality. The data showed strong evidence that the benefits of the vaccine outweigh the potential risks. People aged 5 and above should receive one dose, regardless of their COVID-19 vaccination history. Children aged 6 months to 4 years should receive two doses if they haven't been previously vaccinated, and if they have, they should receive a single dose.

At a recent conference in Romania on the COVID crisis, a credible estimate suggested that there could be 17 million deaths worldwide from the COVID vaccine. This number may seem high, but when you consider the global population, it is not impossible. It is tragic that the vaccine is still being recommended for healthy children who are unlikely to benefit from it and may suffer serious and long-lasting harm. There has never been a proper justification for giving the vaccine to healthy kids, as they are not at high risk of dying from COVID and the vaccine does not prevent transmission. It is concerning that this practice continues even though the emergency situation has passed.

3.1 million Canadian children have received at least one COVID-19 vaccine, increasing their long-term cancer risk. Vaccinated kids are developing turbo cancers like leukemias and brain tumors, previously seen in adults. This elevated cancer risk will affect them for life.

Professor Skerritt asked when the TGA first became aware that two Australian children, aged seven and nine, died of cardiac arrests directly after receiving a COVID vaccination. Senator responded that there are a number of reports of deaths of people of all ages temporally related to vaccination or not related to vaccination, and that the two specific reports were received in the adverse event notification database. They were unable to obtain sufficient information to assess these particular cases in detail, but the information available indicated they were associated with a heart attack, which is not a known adverse event of any of the COVID vaccines. Professor Skerritt pressed, asking if cardiac arrest is not an associated adverse event of vaccination. Senator clarified the point, and Professor Skerritt noted that there are two notes for file relating to both incidents obtained via freedom of information, which appear to draw a conclusion that they were a result of the COVID vaccination. Senator replied that this was incorrect, stating that if they were a result of vaccination, an announcement would have been made, and they were not concluded to be associated. Professor Skerritt then asked, in effect, how often seven- and nine-year-olds die of cardiac arrest. Senator answered that, unfortunately, it is not as uncommon as people might think. In summary, the discussion centers on whether two pediatric deaths occurring shortly after COVID vaccination were causally linked according to the TGA, the availability and interpretation of data from adverse event reports and FOI notes, and the assertion that a death attributed to vaccination would have prompted an official announcement. The conversation also highlights the point that cardiac arrest in young children, while not common, is not as rare as some might assume.

Regulators, including the MHRA, European regulator, and World Health Organization, have found that all three COVID-19 vaccines used in the UK are safe and effective, saving thousands of lives. The vaccine rollout is going well, and the safety system is working. The AstraZeneca vaccine is not recommended for those under 30, but alternatives will be offered to ensure safety. The vaccine has not been tested on children as their risk of significant harm from COVID-19 is low. All data and side effects are being transparently shared. Face masks are recommended in hospitals, care homes, and some other environments. Vaccination not only protects individuals but also reduces transmission and brings us closer to normalcy. The UK regulator is independent and not influenced by external pressure. Leaving the EU allowed the UK to make authorization decisions faster while maintaining safety checks.

None of the vaccines, including the COVID vaccine, have undergone proper testing. No childhood vaccine has completed a placebo-controlled clinical trial with sufficient duration and power to confirm its safety before being administered to millions of children in America. This is not an opinion; it can be verified by anyone visiting the FDA website, where the package inserts and clinical trial documents are available for review.